Speaker
Koenraad Wiedhaup | CEO, Leyden Labs
Koenraad Wiedhaup, founder and CEO of Leyden Labs is committed to helping people strive for a fantastic life by bringing scientific developments to those who need them. He has worked with biopharmaceutical and life science companies as a partner at McKinsey & Company. Together with executive leadership, he developed business and commercial strategies, including launching products and M&A. Prior to McKinsey, Koenraad worked in business development of a San Francisco based biotech company. He has an background in Life Sciences at the Delft and Leiden Universities and holds an MBA from Columbia Business School in New York.
Leyden Labs
We all harbor and spread respiratory viruses. Moreover, we are often in the dark when initial infection and transmission occurs. This is something we have seen in recent years: for influenza, RSV and coronaviruses, we have a very real problem of severe disease and asymptomatic spread.
This is why at Leyden Labs, we want to stop infections early on, at the very gate through which they enter. In the case of respiratory viruses: the nasal mucosa. We have developed an Mucosal Immunity technology platform, through which we can engineer molecules that are effective in the nasal mucosa.
Our company is developing nasal sprays containing antibodies that target respiratory viruses in the nasal mucosa. These sprays aim to:
• Fight the initial infection at the gate: which can prevent onward transmission.
• Protect broadly against existing and new viruses.
• Provide universal protection, regardless of an individual’s immune history or comorbidities.
With our products, we fight viruses where they fight us, to prepare us for future endemic and pandemic threats. We have a pipeline of clinical and pre-clinical candidates for influenza and corona viruses.
The company’s founders are biotechnology veterans who founded and built vaccine pioneer Crucell. Leyden Labs has raised $200M from investors including GV, Casdin Capital, F-Prime, SoftBank, and Byers Capital/Brook Byers.
This is why at Leyden Labs, we want to stop infections early on, at the very gate through which they enter. In the case of respiratory viruses: the nasal mucosa. We have developed an Mucosal Immunity technology platform, through which we can engineer molecules that are effective in the nasal mucosa.
Our company is developing nasal sprays containing antibodies that target respiratory viruses in the nasal mucosa. These sprays aim to:
• Fight the initial infection at the gate: which can prevent onward transmission.
• Protect broadly against existing and new viruses.
• Provide universal protection, regardless of an individual’s immune history or comorbidities.
With our products, we fight viruses where they fight us, to prepare us for future endemic and pandemic threats. We have a pipeline of clinical and pre-clinical candidates for influenza and corona viruses.
The company’s founders are biotechnology veterans who founded and built vaccine pioneer Crucell. Leyden Labs has raised $200M from investors including GV, Casdin Capital, F-Prime, SoftBank, and Byers Capital/Brook Byers.
| Powered by: Hyphen Projects | Let's connect: |
Book a ticket
| |||
| FAQ Contact Us Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
|
Keep me informed
Download our event app
|
© Copyright 2023 by Hyphen Projects